RxDoctor Payments Data

Aaron Brown

Optometrist · Rochester, INNPI 1497241699

Payments from drug & device makers

$1,001in general payments, 2019–2025

Across 42 payments — averaging $23.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$594
  • Coopervision Inc.$93
  • Sun Pharmaceutical Industries Inc.$82
  • Tarsus Pharmaceuticals, Inc.$70
  • Biotissue Holdings Inc.$48
  • Dompe US, Inc.$35
  • plus $79 from 3 others

What the payments were for

  • Food & beverage$1,001100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,001 in reported general payments places this provider in the 60th percentile of 1,318 optometrist providers in Indiana.

See all optometrist providers in Indiana

Medicare billing

Part B allowed, 2024
$208,829
Medicare patients
508
Services billed
2,786

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine30$37,474
XiidraLifitegrast14$26,215
LumiganBimatoprost27$11,996
Travoprost32$6,564
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol13$4,141
Brimonidine Tartrate30$3,614
Prednisolone Acetate128$3,122
Latanoprost265$2,441
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat56$1,108
Doxycycline Hyclate12$978
MoxifloxacinMoxifloxacin Hcl29$940
Dorzolamide Hcl38$903
Timolol Maleate92$652
Azelastine Hcl16$253

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra$14$26,21514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,318 optometrist providers in Indiana.

Other optometrist in Rochester

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →